Compare SCD & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | CGC |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.2M | 401.0M |
| IPO Year | N/A | 2023 |
| Metric | SCD | CGC |
|---|---|---|
| Price | $15.84 | $1.01 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 99.4K | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | ★ 84.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $15.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.79 | $0.84 |
| 52 Week High | $16.18 | $2.38 |
| Indicator | SCD | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 61.14 |
| Support Level | $15.15 | $1.01 |
| Resistance Level | $16.13 | $1.08 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 90.92 | 83.94 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.